Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
White
R M
RM
D017088:AIDS-Related Opportunistic Infections / Q000139:chemically induced*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D018592:Cross-Over Studies; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004337:Drug Carriers; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D008081:Liposomes; D012514:Sarcoma, Kaposi / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D003630:Daunorubicin